Equities Analysts Issue Forecasts for ENTA FY2029 Earnings

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA - Free Report) - Equities researchers at HC Wainwright issued their FY2029 earnings estimates for Enanta Pharmaceuticals in a report released on Tuesday, December 24th. HC Wainwright analyst E. Arce expects that the biotechnology company will earn ($6.62) per share for the year. HC Wainwright has a "Buy" rating and a $18.00 price objective on the stock. The consensus estimate for Enanta Pharmaceuticals' current full-year earnings is ($4.73) per share.

Enanta Pharmaceuticals (NASDAQ:ENTA - Get Free Report) last posted its quarterly earnings results on Monday, November 25th. The biotechnology company reported ($1.36) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.16) by ($0.20). Enanta Pharmaceuticals had a negative return on equity of 73.02% and a negative net margin of 171.57%. The company had revenue of $14.60 million for the quarter, compared to the consensus estimate of $17.99 million. During the same quarter in the previous year, the business earned ($1.33) earnings per share. Enanta Pharmaceuticals's revenue was down 22.8% compared to the same quarter last year.

A number of other equities analysts have also recently issued reports on ENTA. JMP Securities restated a "market outperform" rating and issued a $21.00 price objective (down previously from $22.00) on shares of Enanta Pharmaceuticals in a research report on Tuesday, November 26th. Robert W. Baird dropped their price target on Enanta Pharmaceuticals from $26.00 to $20.00 and set an "outperform" rating for the company in a research note on Tuesday, November 26th. One research analyst has rated the stock with a sell rating, one has issued a hold rating, three have issued a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat.com, Enanta Pharmaceuticals has an average rating of "Moderate Buy" and a consensus target price of $17.25.

Enanta Pharmaceuticals Stock Down 4.2 %

Shares of Enanta Pharmaceuticals stock traded down $0.27 on Wednesday, hitting $6.10. The stock had a trading volume of 241,835 shares, compared to its average volume of 225,231. Enanta Pharmaceuticals has a one year low of $5.70 and a one year high of $17.80. The stock's 50-day simple moving average is $9.52 and its two-hundred day simple moving average is $11.61. The stock has a market cap of $129.28 million, a price-to-earnings ratio of -1.11 and a beta of 0.49.

Insider Buying and Selling at Enanta Pharmaceuticals

In other Enanta Pharmaceuticals news, CEO Jay R. Luly sold 5,142 shares of the firm's stock in a transaction that occurred on Friday, December 6th. The shares were sold at an average price of $8.06, for a total transaction of $41,444.52. Following the completion of the transaction, the chief executive officer now owns 801,638 shares of the company's stock, valued at approximately $6,461,202.28. This trade represents a 0.64 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 13.64% of the company's stock.

Institutional Trading of Enanta Pharmaceuticals

Hedge funds have recently made changes to their positions in the stock. Barclays PLC increased its position in shares of Enanta Pharmaceuticals by 294.2% during the third quarter. Barclays PLC now owns 27,438 shares of the biotechnology company's stock valued at $285,000 after acquiring an additional 20,478 shares in the last quarter. Geode Capital Management LLC raised its stake in shares of Enanta Pharmaceuticals by 3.1% in the third quarter. Geode Capital Management LLC now owns 477,351 shares of the biotechnology company's stock worth $4,946,000 after purchasing an additional 14,575 shares during the last quarter. Krensavage Asset Management LLC lifted its holdings in shares of Enanta Pharmaceuticals by 19.7% during the third quarter. Krensavage Asset Management LLC now owns 1,498,074 shares of the biotechnology company's stock valued at $15,520,000 after purchasing an additional 246,736 shares in the last quarter. Wellington Management Group LLP purchased a new stake in shares of Enanta Pharmaceuticals during the third quarter valued at $360,000. Finally, State Street Corp increased its holdings in Enanta Pharmaceuticals by 6.4% in the 3rd quarter. State Street Corp now owns 449,975 shares of the biotechnology company's stock worth $4,662,000 after buying an additional 27,147 shares in the last quarter. 94.99% of the stock is owned by institutional investors.

About Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.